Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...
Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...
In a phase 3 trial, adding adjuvant belzutifan to standard of care pembrolizumab reduces the chances of clear cell RCC recurrence after nephrectomy, but overall survival data are still immature.
CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...
Patient and physician preferences for treatment in advanced renal cell carcinoma (PEAR): An international, multi-centre discrete choice experiment (DCE). Serum IgG: A novel biomarker for efficacy and ...
Treatment utilization in metastatic renal cell carcinoma (mRCC) following implementation of a national cancer drug list (CDL) drug reimbursement program in Singapore: A real-world single-centre study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results